Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | PYGB | P11216 | 2/20 | 0.33 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 2/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447610 | 1.00 | OGA (0.41) | OGAFBP1GAAMGAMSI | |
| SCHEMBL12972236 | 1.00 | OGA (0.41) | OGAFBP1GAAMGAMSI | |
| SCHEMBL14447602 | 1.00 | OGA (0.41) | OGAFBP1GAAMGAMSI | |
| SCHEMBL388615 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB | |
| SCHEMBL22854031 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB | |
| SCHEMBL24496738 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB | |
| SCHEMBL10111771 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB | |
| SCHEMBL22059921 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB | |
| SCHEMBL24618835 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB | |
| SCHEMBL10182892 | 0.89 | LGALS1 (0.48) | OGAGAALGALS1LGALS3PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018065387-A1 | NOVEL HAMAMELITANNIN ANALOGUES AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2018-04-12 | — | — | WO | disclosed |
| US-8557765-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2013-10-15 | — | — | US | disclosed |
| US-8557765-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2013-10-15 | — | — | US | disclosed |
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2009-12-17 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MLNR, GIPR, GRPR | OGA 4021/4885FBP1 4628/4885GAA 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.